T-cell costimulatory pathways in allograft rejection and tolerance

Immunological Reviews

Volumn 196, Issue , 2003, Pages 85-108

  Rothstein, David M ^a   Sayegh, Mohamed H ^b,c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B7 ANTIGEN; B7 LIGAND; B7H MONOCLONAL ANTIBODY; CALCINEURIN INHIBITOR; CD134 ANTIGEN; CD134 LIGAND MONOCLONAL ANTIBODY; CD137 ANTIGEN; CD137 MONOCLONAL ANTIBODY; CD27 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD70 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; HYBRID PROTEIN; IMMUNOGLOBULIN; LIGAND; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND; PROGRAMMED DEATH 1 LIGAND IMMUNOGLOBULIN; PROTEIN; PROTEIN PROGRAMMED DEATH 1; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOGRAFT; ALLOIMMUNITY; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTING CELL; ANTIGEN STRUCTURE; BINDING AFFINITY; CELL INTERACTION; CHIMERA; CLINICAL TRIAL; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; FUNCTIONAL ASSESSMENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LIGAND BINDING; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; T LYMPHOCYTE; THROMBOEMBOLISM; TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIGENS, CD; GRAFT REJECTION; HUMANS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344984420     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-065X.2003.00088.x     Document Type: Review

References (212)

1. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975;53:27-42.
2. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
3. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:1461-1466.
4. Sayegh MH, Turka LA. The role of T cell costimulatory activation in transplant rejection. N Engl J Med 1998;338:1813-1821.
5. + T cells. Immunol Rev 1998;165:231-247.
6. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001;1:220-228.
7. Michel F, Acuto O. CD28 costimulation: a source of Vav-1 for TCR signaling with the help of SLP-76? Sci STKE 2002;2002:PE35.
8. Rudd CE, Martin M, Schneider H. CTLA-4 negative signaling via lipid rafts: a new perspective. Sci STKE 2002;2002:PE18.
9. Sedwick CE, Altman A. Ordered just so: lipid rafts and lymphocyte function. Sci STKE 2002;2002:RE2.
10. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
11. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-126.
12. Larsen C, Pearson T. The CD40 pathway in allograft rejection, acceptance and tolerance. Curr Opin Immunol 1997;9:641-647.
13. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
14. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-209.
15. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13:559-575.
16. Salama AD, Sayegh MH. Alternative T-cell costimulatory pathways in transplant rejection and tolerance induction: hierarchy or redundancy? Am J Transplant 2003;3:509-511.
17. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 1992;149:380-388.
18. Trambley J, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999;104:1715-1722.
19. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104-106.
20. June CH, Jackson KM, Ledbetter JA, Leiden JM, Lindsten T, Thompson CB. Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. J Autoimmun 1989;2:55-65.
21. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999;283:680-682.
22. Samelson LE. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol 2002;20:371-394.
23. Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 1998;188:199-204.
24. Yamada A, et al. CD28 independent costimulation of T cells in alloimmune responses. J Immunol 2001;167:140-146.
25. Turka LA, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11102-11105.
26. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994;57:1701-1706.
27. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995;181:1869-1874.
28. Lin H, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1806.
29. Pearson T, et al. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism. Transplantation 1995;61:997-1004.
30. Sayegh M, Zheng X-G, Magee C, Hancock W, Turka L. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allografts. Transplantation 1997;64:1646-1650.
31. Glysing-Jensen T, Raisanen-Sokolowski A, Sayegh MH, Russell MH. Chronic blockade of CD28-B7 mediated T cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplantation 1997;164:1641-1645.
32. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999;5:1298-1302.
33. + T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000;164:512-521.
34. Azuma H, et al. Blockade of T cell costimulation prevents development of experimental chronic allograft rejection. Proc Natl Acad Sci USA 1996;93:12439-12444.
35. Russell ME, et al. Chronic cardiac rejection in the Lewis to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996;97:833-838.
36. Chandraker A, Russell ME, Glysing-Jensen T, Willett TA, Sayegh MH. T cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation 1997;63:1053-1058.
37. Chandraker A, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998;101:2308-2318.
38. Li XC, Zand MS, Li Y, Zheng XX, Strom TB. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol 1998;161:2241-2247.
39. Kishimoto K, et al. Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest 2002;109:1471-1479.
40. Mandelbrot DA, et al. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts. J Immunol 1999;163:3753-3757.
41. Szot GL, et al. Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival. Transplantation 2000;69:904-909.
42. Ariyan C, et al. CTLA-4 plays an essential role tolerance mediated by anti-CD45RB. J Immunology (in press).
43. Mandelbrot D, McAdam A, Sharpe A. B7-1 or B7-2 is required to produce the lympho-proliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 1999;189:435-440.
44. -/- mice. Nat Med 2001;7:557-562.
45. + T cells. J Immunol 1999;163:2358-2362.
46. Judge TA, Tang A, Spain LM, Gratiot-Deans J, Sayegh MH, Turka LA. The in vivo mechanisms of action of CTLA4Ig. J Immunol 1996;156:2294-2299.
47. + T cell activation and tolerance in vivo. Am J Transplant 2003;10:1242-1250.
48. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998;161:1659-1663.
49. Wells AD, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999;5:1303-1307.
50. Levisetti MG, et al. Immunosuppressive effects of hCTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997;159:5187-5191.
51. Adams AB, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002;51:265-270.
52. Stamper CC, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001;410:608-611.
53. Collins AV, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002;17:201-210.
54. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996;4:535-543.
55. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-594.
56. Metz DP, Farber DL, Taylor T, Bottomly K. Differential role of CTLA-4 in regulation of resting memory versus naïve CD4 T cell activation. J Immunol 1998;161:5855-5861.
57. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-440.
58. Takahashi T, et al. Immunologie self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-310.
59. Perez V, Parijs LV, Biuckians A, Zheng X, Strom T, Abbas A. Induction of peripheral T cell tolerance in vivo required CTLA-4 engagement. Immunity 1997;6:411-417.
60. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465.
61. Griffin MD, et al. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol 2000;164:4433-4442.
62. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol 2000;164:5319-5327.
63. Martin M, Schneider H, Azouz A, Rudd CE. Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med 2001;194:1675-1681.
64. Chikuma S, Imboden JB, Bluestone JA. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2003;197:129-135.
65. Lee KM, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998;282:2263-2266.
66. Baroja ML, et al. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation. J Immunol 2000;164:49-55.
67. Schneider H, Rudd CE. Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition. Biochem Biophys Res Commun 2000;269:279-283.
68. Baroja ML, et al. Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J Immunol 2002;168:5070-5078.
69. Sho M, et al. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25(+) cells, and the alloreactive T cell done size. J Immunol 2002;169:3744-3751.
70. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999;162:1947-1951.
71. Zheng XX, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined DST and anti-CD 154 mAb treatment. J Immunol 1999;162:4983-4990.
72. Taylor PA, Lees CJ, Waldmann H, Noelle RJ, Blazar BR. Requirements for the promotion of allogeneic engraftment by anti-CD 154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001;98:467-474.
73. Hwang KW, et al. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol 2002;169:633-637.
74. Fecteau S, Basadonna GP, Freitas A, Ariyan C, Sayegh MH, Rothstein DM. CTLA-4 upregulation plays a role in tolerance mediated by CD45. Nat Immunol 2001;2:58-63.
75. Rothstein DM, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001;166:322-329.
76. Chitnis T, et al. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001;107:575-583.
77. Lenschow DJ, et al. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 1995;60:1171-1178.
78. Hancock WW, Sayegh MH, Peach R, Linsley PS, Turka LA. Costimulatory function of CD40L, CD80 and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996;93:13967-13972.
79. Zheng XX, et al. The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol 1997;159:1169-1173.
80. Mandelbrot DA, et al. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest 2001;107:881-887.
81. Furukawa Y, Mandelbrot DA, Libby P, Sharpe AH, Mitchell RN. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am J Pathol 2000;157:473-484.
82. Kim KS, et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol 2001;158:977-986.
83. Grohmann U, et al. CTLA-4-1g regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-1101.
84. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-473.
85. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H Jr. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001;167:5522-5526.
86. Yamada A, Sayegh MH. The CD154-CD40 costimulatory pathway in transplantation. Transplantation 2002;73:S36-S39.
87. Adams AB, Larsen CP, Pearson TC, Newell KA. The role of TNF receptor and TNF superfamily molecules in organ transplantation. Am J Transplant 2002;2:12-18.
88. Blair PJ, et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000;191:651-660.
89. van Essen D, Kikutani H, Gray D. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 1995;378:620-623.
90. Allen RC, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-993.
91. + helper and a T-killer cell. Nature 1998;393:474-478.
92. Parker DC, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995;92:9560-9564.
93. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002;80:477-483.
94. Bishop GA, Hostager BS, Brown KD. Mechanisms of TNF receptor-associated factor (TRAF) regulation in B lymphocytes. J Leukoc Biol 2002;72:19-23.
95. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001;20:6482-6491.
96. Hostager BS, Bishop GA. Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol 1999;162:6307-6311.
97. Larsen CP, et al. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996;61:4-9.
98. Sho M, et al. New insights into the interactions between T cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002;236:667-675.
99. Kirk AD, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94:8789-8794.
100. Kirk AD, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999;5:686-693.
101. Kenyon NS, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999;96:8132-8137.
102. Kenyon NS, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999;48:1473-1481.
103. + T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 2000;69:2609-2612.
104. Shimizu K, Schonbeck U, Mach F, Libby P, Mitchell RN. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000;165:3506-3518.
105. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998;4:1392-1396.
106. Larsen CP, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
107. Sho M, Harada H, Rothstein DM, Sayegh MH. CD45RB-targeting strategies for promoting long-term allograft survival and preventingchronic allograft vasculopathy. Transplantation 2003;75:1142-1146.
108. Yuan X, et al. A novel CD154 monoclonal antibody in acute and chronicrat vascularized cardiac allograft rejection. Transplantation 2002;73:1736-1742.
109. Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001;108:943-948.
110. Wekerle T, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998;187:2037-2044.
111. Wekerle T, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreducutive host treatment. Nat Med 2000;6:464-469.
112. Durham MM, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000;165:1-4.
113. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001;193:1311-1318.
114. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6:114.
115. Hutloff A, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263-266.
116. Yoshinaga SK, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999;402:827-832.
117. Brodie D, et al. LICOS, a primordial costimulatory ligand? Curr Biol 2000;10:333-336.
118. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7. 1 and B7.2, is induced by TNF-alpha. Immunity 1999;11:423-432.
119. Yoshinaga SK, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol 2000;12:1439-1447.
120. Ling V, et al. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol 2000;164:1653-1657.
121. Mages HW, et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 2000;30:1040-1047.
122. Aicher A, et al. Characterization of human inducible costimulator ligand expression and function. J Immunol 2000;164:4689-4696.
123. Coyle AJ, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000;13:95-105.
124. McAdam AJ, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4(+) T cells. J Immunol 2000;165:5035-5040.
125. Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 1999;11:286-293.
126. Akbari O, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002;8:1024-1032.
127. Kopf M, et al. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J Exp Med 2000;192:53-61.
128. Dong C, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001;409:97-101.
129. McAdam AJ, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001;409:102-105.
130. Tafuri A, et al. ICOS is essential for effective T-helper-cell responses. Nature 2001;409:105-109.
131. Ozkaynak E, et al. Importance ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001;2:591-596.
132. Harada H, et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003;112:234-243.
133. Rottman JB, et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001;2:605-611.
134. Shlapatska LM, et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 2001;166:5480-5487.
135. Freeman G, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1-9.
136. Latchman Y, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-268.
137. Ishida M, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 2002;84:57-62.
138. Salama A, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003;198:71-78.
139. Ansari MJ, et al. The programmed death-1 (PD-1) regulatory pathway regulates autoimmune diabetes in NOD mice. J Exp Med 2003;198:63-39.
140. Carter L, et al. PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002;32:634-643.
141. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-151.
142. Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998;10:1563-1572.
143. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, costimulates T cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-1369.
144. Tseng SY, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001;193:839-846.
145. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22:265-268.
146. Nishimura H, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science 2001;291:319-322.
147. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001;98:13866-13871.
148. Ozkaynak E, et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002;169:6546-6553.
149. Gao W, Demirci G, Strom TB, Li XC. Stimulating PD-1 negative signals concurrent with blocking CD154 costimulation induces long-term allograft survival. Transplantation 2003;76:994-999.
150. Ito T, Nayer A, Yagita H, Auchincloss H Jr, Sayegh MH. The role of the inhibitory costimulatory pathway PD-1 in regulating alloimmune responses in vivo [Abstract]. Am J Transplant 2003;3:169.
151. Blazar BR, et al. Blockade of PD-1 pathway engagement accelerates graft-versus-host disease lethality. J Immunol 2003;171:1272-1277.
152. Paterson DJ, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987;24:1281-1290.
153. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO J 1990;9:1063-1068.
154. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, Claassen E, Noelle RJ, Fell HP. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 1993;151:5261-5271.
155. Latza U, et al. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol 1994;24:677-683.
156. Miura S, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 1991;11:1313-1325.
157. Baum PR, et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 1994;13:3992-4001.
158. + T cells with homology to tumor necrosis factor. J Exp Med 1994;180:757-762.
159. Durkop H, Latza U, Himmelreich P, Stein H. Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues. Br J Haematol 1995;91:927-931.
160. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998;161:6510-6517.
161. Weinberg AD, et al. Target organ-specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J Immunol 1994;152:4712-4721.
162. Walker LS, et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med 1999;190:1115-1122.
163. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995;2:507-521.
164. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997;159:3838-3848.
165. Imura A, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996;183:2185-2195.
166. Akiba H, Atsuta M, Yagita H, Okumura K. Identification of rat OX40 ligand by molecular cloning. Biochem Biophys Res Commun 1998;251:131-136.
167. Weinberg AD, Vella AT, Croft M. OX-40: life beyond the effector T cell stage. Semin Immunol 1998;10:471-480.
168. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000;165:3043-3050.
169. Chen AI, et al. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity 1999;11:689-698.
170. Kopf M, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 1999;11:699-708.
171. Pippig SD, et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 1999;163:6520-6529.
172. Murata K, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000;191:365-374.
173. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998;188:297-304.
174. Jember AG, Zuberi R, Liu FT, Croft M. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J Exp Med 2001;193:387-392.
175. Akiba H, et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 2000;191:375-380.
176. Stuber E, Von Freier A, Marinescu D, Folsch UR. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology 1998;115:1205-1215.
177. Brocker T, Gulbranson-Judge A, Flynn S, Riedinger M, Raykundalia C, Lane P. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol 1999;29:1610-1616.
178. Weinberg AD, et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996;2:183-189.
179. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999;162:1818-1826.
180. Higgins LM, McDonald SA, Whittle N, Crockett N, Shields JG, MacDonald TT. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 1999;162:486-493.
181. Nohara C, et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 2001;166:2108-2115.
182. Akiba H, et al. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol 1999;162:7058-7066.
183. Yuan X, et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003;170:2949-2955.
184. Blazar BR, et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 2003;101:3741-3748.
185. Pollok KE, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993;150:771-781.
186. Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995;155:3360-3367.
187. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998;190:167-172.
188. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997;158:2600-2609.
189. Goodwin RG, et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB. a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993;23:2631-2641.
190. DeBenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28-T lymphocytes by 4-1BB ligand. J Immunol 1997;158:551-559.
191. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, Kwon BS. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 1994;24:367-374.
192. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
193. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999;162:5037-5040.
194. DeBenedette MA, et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 1999;163:4833-4841.
195. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol 2000;30:392-402.
196. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999;190:1535-1540.
197. Kim YJ, Kim SH, Mantel P, Kwon BS. Human 4-1BB regulates CD28 costimulation to promote Th1 cell responses. Eur J Immunol 1998;28:881-890.
198. Cannons JL, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313-1324.
199. + T cells. J Immunol 1997;158:3081-3089.
200. DeBenedette MA, et al. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1995;181:985-992.
201. Tan JT, et al. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation 2000;70:175-183.
202. + T cells. Am J Transplant 2003;3:543-551.
203. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 2001;166:3174-3183.
204. Gravestein LA, Borst J. Tumor necrosis factor receptor family members in the immune system. Semin Immunol 1998;10:423-434.
205. Takeda K, et al. CD27-mediated activation of murine NK cells. J Immunol 2000;164:1741-1745.
206. Tesselaar K, Gravestein LA, van Schijndel GM, Borst J, van Lier RA. Characterization of murine CD70, the ligand of the TNF receptor family member CD27. J Immunol 1997;159:4959-4965.
207. Hendriks J, Gravestein LA, Tesselaar K, van Lier RAW, Schumacher TNM, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000;1:433-440.
208. Schmitter D, Bolliger U, Hallek M, Pichert G. Involvement of the CD27-CD70 costimulatory pathway in allogeneic T-cell response to follicular lymphoma cells. Br J Haematol 1999;106:64-70.
209. Oshima H, et al. Characterization of murine CD70 by molecular cloning and mAb. Int Immunol 1998;10:517-526.
210. Jacquot S. CD27/CD70 interactions regulate T dependent B cell differentiation. Immunol Res 2000;21:23-30.
211. Nakajima A, et al. Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2000;109:188-196.
212. + T cells, (submitted).